SHetA2 for Treatment of Cervical Intraepithelial Neoplasia
SHetA2 therapy is an investigational oral small-molecule drug designed to treat HPV-related precancerous cervical lesions and advanced solid tumors by targeting heat shock proteins without high toxicity . It was co-developed by the Indian Council of Medical Research (ICMR) National Institute of Cancer Prevention and Research and the University of Oklahoma. About the Technology: SHetA2 selectively targets HPV-driven oncogenesis, with the potency to kill cancer cells while sparing normal cells. It targets mortalin, Hsc70, and Grp78 to disrupt HSP70/E7 complexes, reduce p16 expression, and inhibit tumor growth. SHetA2 has shown strong safety, tolerability, and improved bioavailability in preclinical and Phase 1 studies. Delivered orally or as a vaginal suppository, it offers a cost-effective, non-invasive, take-home therapy, well-suited for global use, including LMICs. Need and utility of the Technology from Public health perspective: SHetA2 inhibits HPV induced tumor growth ...